Jasper Therapeutics, Inc. (JSPRW)

US — Healthcare Sector
Peers: ROIVW  SABSW  NRXPW  CELUW  EFTRW 

Automate Your Wheel Strategy on JSPRW

With Tiblio's Option Bot, you can configure your own wheel strategy including JSPRW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol JSPRW
  • Rev/Share 0.0805
  • Book/Share 2.8964
  • PB 1.7711
  • Debt/Equity 0.0613
  • CurrentRatio 4.3112
  • ROIC -1.793

 

  • MktCap 77063373.0
  • FreeCF/Share -4.8156
  • PFCF -1.0972
  • PE 5.4502
  • Debt/Assets 0.045
  • DivYield 0
  • ROE 0.1907

 

  • Rating S-
  • Score 5
  • Recommendation Strong Buy
  • P/E Score 3
  • DCF Score 5
  • P/B Score 5
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Jasper Therapeutics, Inc. (JSPRW)

  • IPO Date
  • Website https://www.jaspertherapeutics.com/
  • Industry Biotechnology
  • CEO Mr. Ronald A. Martell
  • Employees 64
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.